优化重症监护室药师药物管理与死亡率的关系
这项多中心观察性研究纳入美国、约旦、沙特阿拉伯64个中心的28,795例ICU成人患者,收集2023年8月至2025年1月的数据。主要暴露为按患者计算的药师与患者比例(ICU期间平均值),次要暴露为ICU期间至少1天未接受药师提供的综合药物管理(CMM)。主要终点为住院死亡率。结果显示,药师与患者比例每增加1例,住院死亡几率增加1%(OR 1.01,95%CI 1.00-1.01,p=0.04);至少1天未接受CMM者死亡几率增加20%(OR 1.20,95%CI 1.03-1.40,p=0.02)。
要点
- 在64个中心28,795例ICU成人中,药师与患者比例中位数为1:17(IQR 13-23)。
- 药师与患者比例每增加1例,住院死亡几率增加1%(OR 1.01,95%CI 1.00-1.01,p=0.04)。
- ICU期间至少1天未接受药师CMM,住院死亡几率增加20%(OR 1.20,95%CI 1.03-1.40,p=0.02)。
- 药师与患者比例为1:15.1-46的患者,较1:7-15者住院死亡几率增加10%(OR 1.10,95%CI 1.00-1.22)。
- 研究为观察性设计,提示药师配置与每日CMM和住院死亡率存在关联,需前瞻性验证。
适用人群与场景
- ICU成人患者,来自美国、约旦、沙特阿拉伯64个中心,2023年8月至2025年1月入组。
诊断标准与关键阈值
- 主要暴露:按患者计算的药师与患者比例,取ICU期间平均值。
- 次要暴露:ICU期间至少1天未接受药师提供的综合药物管理(CMM)。
- 主要终点:住院死亡率。
处置流程与药物剂量
- 原文未提及
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 多中心观察性研究,64个中心,28,795例ICU成人患者。
- 药师与患者比例中位数1:17(IQR 13-23)。
- 比例每增加1例,住院死亡几率增加1%(OR 1.01,95%CI 1.00-1.01,p=0.04)。
- 至少1天未接受CMM,住院死亡几率增加20%(OR 1.20,95%CI 1.03-1.40,p=0.02)。
- 比例1:15.1-46较1:7-15,住院死亡几率增加10%(OR 1.10,95%CI 1.00-1.22)。
证据类型、等级与局限
- 研究类型:多中心观察性研究。
- 证据等级或推荐强度:原文未提及。
- 局限:观察性设计,无法证实因果关系;原文未提及其他局限。
对床旁实践的改变
- 提示ICU应关注药师配置比例和每日CMM的落实,避免比例过高或CMM中断。
- 适用与不适用人群:原文未明确排除人群,应结合本院药师资源个体化判断。
- 常见陷阱:不能将观察性关联直接作为因果推荐,需前瞻性研究验证。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Medication-related morbidity due to inappropriate prescribing, delays in appropriate treatment, and adverse drug events contributes to ICU patient mortality. Comprehensive medication management (CMM) is a care standard provided by pharmacists in collaboration with the interprofessional team. Optimizing ICU pharmacist workload via the pharmacist-to-patient ratio while ensuring daily CMM may reduce mortality.
RESEARCH QUESTION: Is ICU pharmacist staffing, measured by the pharmacist-to-patient ratio and absence of CMM, associated with in-hospital mortality among critically ill adults?
STUDY DESIGN AND METHODS: Adults admitted to an ICU from 64 centers (in the United States, Jordan, and Saudi Arabia) were enrolled in a multicenter observational study that collected patient and team staffing data from August 2023-January 2025. The primary outcome was in-hospital mortality. The primary exposure was the pharmacist-to-patient ratio calculated per patient, averaged over the ICU stay. A secondary exposure was the absence of CMM for at least 1 day of the ICU stay. Multivariable generalized estimating equations (GEE) were used to estimate associations with in-hospital mortality, accounting for clustering by center and adjusting for patient-, ICU-, and hospital-level covariates.
RESULTS: Among 28,795 patients enrolled, the median (IQR) pharmacist-to-patient ratio was 1:17 (13-23). Each one-patient increase in the pharmacist-to-patient ratio was associated with a 1% increase in the odds of in-hospital mortality (Odds Ratio [OR] 1.01, 95% Confidence Interval [CI] 1.00-1.01, p=0.04). Patients who did not receive pharmacist-delivered CMM for at least 1 day of the ICU stay had 20% higher odds of in-hospital mortality (OR 1.20, 95% CI 1.03-1.40, p=0.02). Patients cared for at a pharmacist-to-patient ratio of 1:15.1-46 had 10% higher odds of mortality compared to those cared for at a ratio of 1:7-15 (OR 1.10, 95% CI 1.00-1.22).
INTERPRETATION: Increasing pharmacist-to-patient ratios and the absence of pharmacist CMM every day were both associated with increased in-hospital mortality.
参考来源
- Smith SE, Henry KR, Heavner MS, et al. Optimization of Pharmacist Medication Management and Mortality in the Intensive Care Unit. Chest. 2026. PMID: 42810430. doi:10.1016/j.chest.2026.09.027
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。